In vivo, 9 induced tumorregression in an intracranial patient-derived xenograft (PDX) murinemodel suggesting it as a potential lead for the treatment of localizedand metastatic non-small-cell lung cancer (NSCLC) driven by activatingmutant bearing EGFR. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.